United Therapeutics Corpo... (UTHR)
NASDAQ: UTHR
· Real-Time Price · USD
298.42
3.82 (1.30%)
At close: May 05, 2025, 3:59 PM
298.70
0.09%
After-hours: May 05, 2025, 07:35 PM EDT
1.30% (1D)
Bid | 292 |
Market Cap | 13.46B |
Revenue (ttm) | 2.99B |
Net Income (ttm) | 1.21B |
EPS (ttm) | 24.63 |
PE Ratio (ttm) | 12.12 |
Forward PE | 10.12 |
Analyst | Buy |
Ask | 306 |
Volume | 231,507 |
Avg. Volume (20D) | 518,228 |
Open | 296.61 |
Previous Close | 294.60 |
Day's Range | 293.17 - 299.45 |
52-Week Range | 256.08 - 417.82 |
Beta | 0.63 |
About UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 1999
Employees 1,305
Stock Exchange NASDAQ
Ticker Symbol UTHR
Website https://www.unither.com
Analyst Forecast
According to 12 analyst ratings, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is $350, which is an increase of 17.28% from the latest price.
Stock ForecastsEarnings Surprise
United Therapeutics has released their quartely earnings
on Apr 30, 2025:
2 months ago
-10.8%
United Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
8 months ago
+3.04%
United Therapeutics shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $400 to $572.